Petros Pharmaceuticals Statistics
Share Statistics
Petros Pharmaceuticals has 10.01M shares outstanding. The number of shares has increased by 355% in one year.
| Shares Outstanding | 10.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 4.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.13M |
| Failed to Deliver (FTD) Shares | 1.06K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 199.19K, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 199.19K |
| Short % of Shares Out | 1.99% |
| Short % of Float | 2.18% |
| Short Ratio (days to cover) | 0.72 |
Valuation Ratios
The PE ratio is -0.38 and the forward PE ratio is -0.27.
| PE Ratio | -0.38 |
| Forward PE | -0.27 |
| PS Ratio | 0.53 |
| Forward PS | 0.3 |
| PB Ratio | 0.25 |
| P/FCF Ratio | -0.4 |
| PEG Ratio | n/a |
Enterprise Valuation
Petros Pharmaceuticals Inc. has an Enterprise Value (EV) of -1.99M.
| EV / Earnings | 0.24 |
| EV / Sales | -0.34 |
| EV / EBITDA | 0.47 |
| EV / EBIT | 0.15 |
| EV / FCF | 0.26 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.89 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.64 |
| Total Debt / Capitalization | 39.1 |
| Cash Flow / Debt | -0.95 |
| Interest Coverage | -25.4 |
Financial Efficiency
Return on equity (ROE) is -0.65% and return on capital (ROIC) is -65.6%.
| Return on Equity (ROE) | -0.65% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -65.6% |
| Revenue Per Employee | 277.26K |
| Profits Per Employee | -388.72K |
| Employee Count | 21 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.01 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.77% in the last 52 weeks. The beta is 2.28, so Petros Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 2.28 |
| 52-Week Price Change | -73.77% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.45 |
| Relative Strength Index (RSI) | 45.23 |
| Average Volume (20 Days) | 2.04M |
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 5.82M and earned -8.16M in profits. Earnings per share was -6.35.
| Revenue | 5.82M |
| Gross Profit | 4.19M |
| Operating Income | -13.62M |
| Net Income | -8.16M |
| EBITDA | -4.21M |
| EBIT | -13.62M |
| Earnings Per Share (EPS) | -6.35 |
Balance Sheet
The company has 13.34M in cash and 8.28M in debt, giving a net cash position of 5.06M.
| Cash & Cash Equivalents | 13.34M |
| Total Debt | 8.28M |
| Net Cash | 5.06M |
| Retained Earnings | -98.89M |
| Total Assets | 20.69M |
| Working Capital | -1.84M |
Cash Flow
In the last 12 months, operating cash flow was -7.63M and capital expenditures -1, giving a free cash flow of -7.63M.
| Operating Cash Flow | -7.63M |
| Capital Expenditures | -1 |
| Free Cash Flow | -7.63M |
| FCF Per Share | -3.5 |
Margins
Gross margin is 71.98%, with operating and profit margins of -233.88% and -140.2%.
| Gross Margin | 71.98% |
| Operating Margin | -233.88% |
| Pretax Margin | -140.2% |
| Profit Margin | -140.2% |
| EBITDA Margin | -72.34% |
| EBIT Margin | -233.88% |
| FCF Margin | -130.99% |
Dividends & Yields
PTPI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1984.38% |
| FCF Yield | -239.4% |
Analyst Forecast
The average price target for PTPI is $4, which is 1150% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 1150% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 1, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 1, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -7.48 |
| Piotroski F-Score | 3 |